Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Chiome Bioscience's Enterprise Value is 円5,510.2 Mil.
Chiome Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was 円0.0 Mil. Therefore, Chiome Bioscience's EV-to-FCF for today is .
The historical rank and industry rank for Chiome Bioscience's EV-to-FCF or its related term are showing as below:
TSE:4583'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.65 Med: 0 Max: 0
Current: -5.65
TSE:4583's EV-to-FCF is ranked worse than 100% of 320
companies
in the Biotechnology industry
Industry Median: 17.905
vs TSE:4583: -5.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chiome Bioscience's PE Ratio (TTM) for today is calculated as:
Chiome Bioscience's share price for today is 円84.00.
Chiome Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-13.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Chiome Bioscience EV-to-FCF Related Terms
Chiome Bioscience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Chiome Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4583 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Chiome Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiome Bioscience EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chiome Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Chiome Bioscience's EV-to-FCF falls into.
Chiome Bioscience's current Enterprise Value is 円5,510.2 Mil.
Chiome Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Chiome Bioscience (TSE:4583) Overvalued in 2026?
Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued.
The current stock price of 円84.00 is trading 5% below its estimated GF Value™ of 円88.40.
GuruFocus considers Chiome Bioscience to be Fairly Valued.
Key valuation signals for TSE:4583:
EV-to-FCF:
GF Value™: 円88.40 vs. price of 円84.00 (5% below fair value)
No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
52GF Score
Get the complete analysis for TSE:4583
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4583 has been successfully added to your 
